<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Implantable cardioverter-defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) significantly reduce mortality in patients with depressed left ventricular ejection fraction (LVEF) and <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) </plain></SENT>
<SENT sid="1" pm="."><plain>However, shortcomings of LVEF to accurately identify those at greatest risk of ventricular tachyarrhythmias have led to the pursuit of alternative means to refine qualification criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="2" pm="."><plain>It is well established that imaging the cardiac <z:mp ids='MP_0008912'>nervous</z:mp> system with(123)I meta-iodobenzylguanidine ((123)I-mIBG) provides incremental prognostic value in patients with HF beyond LVEF </plain></SENT>
<SENT sid="3" pm="."><plain>Whether (123)I-mIBG will also play an important role for identifying and/or predicting sustained ventricular tachyarrhythmias in patients with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and determining those who may benefit from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation is currently under investigation </plain></SENT>
<SENT sid="4" pm="."><plain>Novel imaging approaches that pinpoint the site of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and guide <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> ablation are presented </plain></SENT>
</text></document>